

MMCOA Board of Directors

President
Kathlyn Wee
CEO
UnitedHealthcare
of the Mid-Atlantic, Inc.

Vice President/ Secretary Vincent M. Ancona President Wellpoint

Treasurer
Edward Kumian
CEO
Priority Partners MCO,
Inc.

Angelo D. Edge CEO Aetna Better Health

Mike Rapach President & CEO CareFirst Community Health Plan Maryland

Jai Seunarine CEO Jai Medical Systems

Shannon McMahon

Executive Director,

Medicaid Policy

Kaiser Permanente - MidAtlantic States

Jason Rottman CEO Maryland Physicians Care

Lesley Wallace
Executive Director
MedStar Family Choice,
Inc.

House Bill 382 - Pharmacy Benefits Administration - Maryland Medical Assistance Program and Pharmacy Benefits Managers

UNFAVORABLE

House Health & Government Operations Committee March 2, 2023

Thank you for the opportunity to submit testimony in opposition to House Bill 382 – Pharmacy Benefits Administration - Maryland Medical Assistance Program and Pharmacy Benefits Managers.

The Maryland Managed Care Organization Association (MMCOA), which is comprised of all nine MCOs that serve Medicaid, is committed to ensuring access to the prescription drugs and devices that our members depend on for their health. Maryland's nine MCOs serve over 1.5 million Marylanders through the Medicaid HealthChoice program, and through our management of the prescription drug benefit, including costly specialty drugs, provide access to the prescription drugs needed by our members at a lower cost, allowing the State to continue to provide this valuable and necessary service. By implementing a universal reimbursement rate for PBM services, free market principles will be undermined and our ability to produce cost savings for the Medicaid program diminished.

While we applaud the bill sponsor's effort to examine ways in which the Medicaid pharmacy spend can be decreased while ensuring access to needed therapies, there are other initiatives that have recently been implemented in the Medicaid pharmacy program, and we strongly encourage the Committee to examine their impact before making additional changes to the delivery of the pharmacy benefit. These measures include the elimination of the spread pricing model, the implementation of the pharmacy appeals and grievance process, and the funding of the Small Rural Pharmacy Grants Program. These cost-savings pharmacy initiatives are in the relatively early stages of utilization and their impact must be evaluated and understood before more measures – including those proposed in HB 382- are adopted, perhaps to the detriment of the program's quality and service to its members.

MMCOA looks forward to continued collaboration with the State as we work to identify ways to improve access to affordable high-quality care for all Medicaid participants.

Please contact Jennifer Briemann, Executive Director of MMCOA, with any questions regarding this testimony at jbriemann@marylandmco.org.